Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Department of Pathology and Laboratory Medicine, |
RCV000791519 | SCV005918822 | likely pathogenic | Li-Fraumeni syndrome | criteria provided, single submitter | clinical testing | ||
| Baylor Genetics | RCV003472330 | SCV004204276 | pathogenic | Adrenocortical carcinoma, hereditary | 2022-08-19 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000791519 | SCV000930772 | pathogenic | Li-Fraumeni syndrome | 2025-08-11 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 3 of the TP53 gene. It does not directly change the encoded amino acid sequence of the TP53 protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with Li-Fraumeni syndrome (PMID: 11420676, 24382691, 28681140). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS3-11 C>G. ClinVar contains an entry for this variant (Variation ID: 638852). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
| Dr. |
RCV005901946 | SCV006902878 | not provided | Uterine corpus endometrial carcinoma | no classification provided | in vitro |